major revision

The authors have provided detailed description of the role of PD-1/PD-L1 and application of PD-1/PD-L1 inhibitor in lymphoma in the first two chapter. However, the relationship between PD-1/PD-L1 pathway and IL-17A in the progress of lymphoma have not been discussed toughly. It may be a little confused for the readers why the authors want to focus on IL-17A but not other interleukins. The authors may need to highlight the significance of this review. The manuscript would be more professional if avoiding colloquial writing.